Rebecca (Reba) L. Rabenstein > Latham & Watkins > Austin, United States > Lawyer Profile
Latham & Watkins Offices

301 CONGRESS AVENUE
SUITE 900
AUSTIN, TEXAS
TEXAS
United States
- Firm Profile
- Go to...
Rebecca (Reba) L. Rabenstein

Position
Dr. Reba Rabenstein advises clients regarding complex intellectual property and trade secret litigation, arbitration, and strategy across industries, with a particular focus on leading branded pharmaceutical and biotechnology companies.
Reba is a seasoned trial attorney representing clients at all stages of litigation, including pre-suit investigation, litigation, trial, and appeal. She has gone to trial in multiple district courts, including the District of Delaware, the Southern District of New York, and in the District of Massachusetts, where she participated in the first virtual patent trial in that district.
Having worked both for patentees and patent defendants, Reba helps her clients strategically navigate cutting-edge legal issues to achieve successful outcomes.
For pharmaceutical and biotechnology companies, she regularly handles cases involving:
-
- Regenerative medicine
- Gene therapy
- Molecular biological techniques
- Small molecule pharmaceuticals
Drawing on her academic experience in cellular and molecular biology, physiology, and pharmacology, she is well-positioned to understand the science and translate it to judges and juries. In addition, Reba leverages her litigation experience to advise clients on due diligence matters and business strategies regarding intellectual property.
Prior to joining Latham, Reba served as a law clerk to Chief Judge Kimberly A. Moore of the United States Court of Appeals for the Federal Circuit. She earned her JD from the University of Michigan Law School, where she served as executive note editor of the Michigan Telecommunications and Technology Law Review.
As a result of her graduate and undergraduate research and various collaborative efforts, Reba has co-authored several scientific articles.
Top Tier Firm Rankings
- Insurance > Advice to policyholders
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Finance > Capital markets: high-yield debt offerings
- Antitrust > Cartel
- International trade and national security > CFIUS
- Antitrust > Civil litigation/class actions: defense
- Finance > Commercial lending
- Intellectual property > Copyright
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy transactions: electric power
- Energy > Energy transactions: oil and gas
- Environment > Environment: litigation
- Environment > Environment: regulatory
- Environment > Environment: transactional
- Finance > Fintech
- Real estate > Land use/zoning
- Environment > Environment: regulatory
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Dispute resolution > Financial services litigation
- Environment > Environment: regulatory
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Media, technology and telecoms > Media and entertainment: litigation
- Media, technology and telecoms > Media and entertainment: transactional
- Antitrust > Merger control
- Environment > Environment: regulatory
- Environment > Environment: regulatory
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (full coverage)
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Finance > Project finance
- Real estate > Real estate
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Securities litigation: defense
- Industry focus > Sport
- Finance > Structured finance: derivatives and structured products
- Media, technology and telecoms > Technology transactions
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: contentious
- Tax > US taxes: non-contentious
Firm Rankings
- M&A/corporate and commercial > Corporate governance
- International trade and national security > Customs, export controls and economic sanctions
- Energy > Energy regulation: electric power
- Energy > Energy regulation: oil and gas
- Dispute resolution > General commercial disputes
- Government > Government contracts
- Insurance > Insurance: non-contentious
- Dispute resolution > International litigation
- Investment fund formation and management > Private equity funds (including venture capital)
- Healthcare > Service providers
- Finance > Structured finance: securitization
- M&A/corporate and commercial > Venture capital and emerging companies
- Dispute resolution > Financial services litigation
- Healthcare > Health insurers
- Dispute resolution > Leading trial lawyers
- Dispute resolution > International arbitration
- Intellectual property > Trademarks: litigation
- Finance > Financial services regulation
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Dispute resolution > Corporate investigations and white-collar criminal defense
- M&A/corporate and commercial > Shareholder activism